Chasing my Cure: Leveraging serum proteomics to identify novel therapeutic approaches and predictive biomarkers

Supported by:

20 January 2022

Shares

13

Share via

• Facebook
• Like
• Twitter
• Pinterest
• LinkedIn
• Digg
• Del
• Tumblr
• VKontakte
• Print
• Email
• Reddit
• Buffer
• Love This
• Weibo
• Pocket
• Xing
• Odnoklassniki
• WhatsApp
• Meneame
• Blogger
• Amazon
• Yahoo Mail
• Gmail
• AOL
• Newsvine
• HackerNews
• Evernote
• MySpace
• Mail.ru
• Viadeo
• Line
• Flipboard
• Comments
• Yummly
• SMS
• Viber
• Telegram
• Subscribe
• Skype
• Facebook Messenger
• Kakao
• LiveJournal
• Yammer
• Edgar
• Fintel
• Mix
• Instapaper
• Copy Link

About this webinar

Dr David Fajgenbaum, the Founding Director of the Center for Cytokine Storm Treatment & Laboratory at the University of Pennsylvania and national bestselling author of Chasing My Cure: A Doctor’s Race to Turn Hope Into Action, shares his groundbreaking work to advance precision medicine for Castleman disease, a cytokine storm disorder that he is battling as a physician, researcher, advocate and patient. Combining SomaScan proteomic and other -omic analyses with cutting-edge bioinformatic approaches, Fajgenbaum has discovered novel predictive biomarkers of treatment response and novel treatment approaches, including one that is saving his life and others.

Learning outcomes of this webinar

• The potential for unbiased serum proteomic analyses to improve understanding of the pathologic mechanisms of a poorly understood, inflammatory disease (idiopathic multicentric Castleman disease)
• How SomaScan can be leveraged to discover biomarkers that can predict which patients will respond to a given treatment
• How SomaScan can be leveraged to identify novel therapeutic targets and promising new or repurposed treatment approaches
• The importance of academic-industry-advocacy collaborations to leverage biospecimens collected from clinical trials to improve understanding and treatment of rare disorders.

Our speaker

David Fajgenbaum, MD, MBA, MSc
Assistant Professor of Medicine, Translational Medicine & Human Genetics, University of Pennsylvania
Founding Director, Center for Cytokine Storm Treatment & Laboratory (CSTL)
Associate Director, Patient Impact, Orphan Disease Center, University of Pennsylvania
Co-Founder & President, Castleman Disease Collaborative Network (CDCN)

David Fajgenbaum, MD, MBA, MSc, is an Assistant Professor of Medicine at the University of Pennsylvania, Founding Director of the Center for Cytokine Storm Treatment & Laboratory (CSTL), Associate Director of Patient Impact for the Penn Orphan Disease Center and co-Founder/President of the Castleman Disease Collaborative Network (CDCN). He is also the national bestselling author of ‘Chasing My Cure: A Doctor’s Race to Turn Hope Into Action’ and a patient battling idiopathic multicentric Castleman disease (iMCD). He is in his longest remission ever thanks to a precision treatment that he identified, which had never been used before for iMCD. Fajgenbaum launched the CORONA project in March 2020 to identify and track treatments for COVID-19. Today, CORONA is the world’s largest database of COVID-19 treatments, including more than 400 medications that have been administered to more than 280,000 patients. Fajgenbaum has published scientific papers in high-impact journals such as the New England Journal of Medicine, Journal of Clinical Investigation and Blood. To advance drug repurposing, he is co-directing an FDA/NIH/C-Path public-private partnership called the CURE Drug Repurposing Collaboratory and leading an effort for rare disease repurposing in collaboration with the Chan Zuckerberg Initiative.